Switching From Ozempic to Mounjaro: Restart the Ladder, Fix the Insulin

Last reviewed 12 August 2026 · Educational, not medical advice · Dose changes, and especially insulin adjustments, are a decision for your prescriber · No sponsorships, no affiliate links

You restart the ladder, you do not transfer your dose

There is no official conversion between semaglutide and tirzepatide doses. Neither manufacturer publishes one and the FDA has never issued one, because these were approved as separate therapies rather than interchangeable products. The receptor difference is why: tirzepatide activates GIP as well as GLP-1, so the dose-response curves are not parallel and equivalence at one step would not predict equivalence at the next.

In practice, prescribers restart tirzepatide at the bottom of its ladder regardless of where you finished on semaglutide, then titrate on response. Being GLP-1-adapted usually makes that climb easier than a first-ever start, but it does not let you skip it. The usual sequencing keeps the weekly rhythm intact, with the first tirzepatide dose about a week after the last semaglutide dose.

One observation from reported practice worth carrying into the conversation: patients who were stable at the top of the semaglutide ladder often settle at tirzepatide 10 to 12.5 mg rather than needing 15 mg. The top dose is a ceiling, not a destination.

The insulin and sulfonylurea problem

This is the part of the switch with real safety content, and it is the reason this is not a self-managed change.

Neither semaglutide nor tirzepatide causes hypoglycaemia on its own, because both stimulate insulin release only when glucose is elevated. Both cause it readily in combination with insulin or a sulfonylurea such as gliclazide or glimepiride. Moving to a more potent agent means the background regimen that was correct on semaglutide is likely to be too much on tirzepatide.

The practical consequences: expect your prescriber to reduce insulin or sulfonylurea doses at the switch and again at each escalation, expect to test more often through the transition, and know the symptoms of a low before you start rather than after.

What you gain, and what you give up

You gain glycaemic and weight efficacy. SURPASS-2 is unambiguous on both, and the composite endpoint gap - 60% against 22% - is one of the largest margins in the diabetes literature. Real-world data agrees on direction: a propensity-matched cohort of more than 18,000 US patients found 12-month weight change of -15.3% on tirzepatide against -8.3% on semaglutide.

You give up organ-specific evidence. Ozempic carries a chronic kidney disease indication in type 2 diabetes, granted on the FLOW trial, and reduced cardiovascular events against placebo in SUSTAIN-6. Mounjaro has SURPASS-CVOT - more than 13,000 patients over 4.5 years - where it was non-inferior to dulaglutide with an 8% lower event rate. That is a large, reassuring trial, but non-inferiority against an older drug is a weaker claim than superiority against placebo, and tirzepatide has no kidney indication at all.

For someone with albuminuria or a declining eGFR, that is the whole decision, and no amount of extra HbA1c reduction offsets it. For someone whose kidneys are fine and whose HbA1c is not, the trade goes the other way.

One caveat about SURPASS-2 worth knowing

The trial capped semaglutide at 1 mg, which was the highest approved Ozempic dose when it was designed. The ceiling is now 2 mg. Nobody has run tirzepatide against semaglutide 2 mg, so if you are currently at 2 mg and doing reasonably well, the real gap is narrower than the headline numbers suggest.

It is probably not narrow enough to change the direction. SURMOUNT-5, which tested both molecules at their full obesity ceilings, still favoured tirzepatide by 6.5 percentage points of body weight. But if you have not yet tried 2 mg, that is a cheaper and simpler experiment than switching molecules.

What to expect through the transition

• Gastrointestinal side effects return during re-titration. Nausea and constipation cluster after each dose increase rather than at steady state. Being GLP-1-adapted helps but does not eliminate it.
• Glucose may swing in both directions in the first weeks - higher while you are at a low tirzepatide dose, lower once you climb, particularly if background medication has not been adjusted.
• Twelve to twenty weeks to a maintenance dose, depending on where you stop. Judging the switch before then is judging an incomplete titration.
• No cost saving. At self-pay rates, Mounjaro is $499 a month at every dose and Ozempic is $499 at 2 mg. If you are paying cash, this switch is cost-neutral at maintenance - and worth asking whether the obesity-labelled tirzepatide, which sells for $299 to $449, is clinically appropriate for you instead.

Through the transition, the log is a safety device

On most switches, tracking is about knowing whether the drug is working. On this one it is about not having a hypoglycaemic episode. If you take insulin or a sulfonylurea, you are changing the potency of one drug while the doses of another stay where they were - and the correction happens in stages, at every escalation, over three or four months.

What that requires is unglamorous and non-negotiable: glucose readings with times, every GLP-1 dose change with its date, and every insulin or sulfonylurea adjustment written down as it happens. Expect the numbers to move in both directions early - higher while you sit at a low tirzepatide dose, lower once you climb, sharply lower if background medication has not been walked down to meet it. A prescriber can titrate safely against that record. Against a recollection of a rough fortnight, nobody can.

Zenday App tops our GLP-1 app ranking at 4.55/5 and is the one we would hand to someone making this change: doses, food, activity, and side-effect days in one place, working from first injection through maintenance, so the transition sits in the same log as everything before it. For the endocrinology appointment where the insulin plan actually gets rewritten, Shotsy turns the same period into a clinician-ready PDF export. In a switch where the safety question outranks the efficacy question, the export is not administrative tidiness - it is the input your prescriber is working from.

What the evidence does not show

• No trial has studied switching between these drugs. Practical statements here come from pharmacology, head-to-head efficacy data, and reported prescribing practice.
• No validated dose equivalence exists.
• No head-to-head at current ceilings - SURPASS-2 tested semaglutide 1 mg, not 2 mg.
• No head-to-head on hard outcomes. SURPASS-2 measured HbA1c and weight over 40 weeks, not heart attacks or kidney failure.

Before you switch, ask your prescriber

• Should we try Ozempic 2 mg first, if I have not been there?
• How are we adjusting my insulin or sulfonylurea at the switch and at each escalation?
• Do my kidney numbers argue for staying on semaglutide?
• What is my target tirzepatide dose, and how will we know we have reached it?
• How do we avoid a supply gap while the prescription changes?

Method and sources

Efficacy figures come from SURPASS-2, SURPASS-CVOT, SUSTAIN-6, FLOW, SURMOUNT-5, and the JAMA Internal Medicine propensity-matched cohort as published. There is no trial of switching between these products. Prices are US manufacturer self-pay rates read on 12 August 2026. We take no money from either manufacturer and run no affiliate links. For the underlying comparison, see Mounjaro vs Ozempic; for the molecule-level view of the same switch, see semaglutide to tirzepatide.